pirenzepine has been researched along with Diabetes Mellitus in 20 studies
Pirenzepine: An antimuscarinic agent that inhibits gastric secretion at lower doses than are required to affect gastrointestinal motility, salivary, central nervous system, cardiovascular, ocular, and urinary function. It promotes the healing of duodenal ulcers and due to its cytoprotective action is beneficial in the prevention of duodenal ulcer recurrence. It also potentiates the effect of other antiulcer agents such as CIMETIDINE and RANITIDINE. It is generally well tolerated by patients.
Diabetes Mellitus: A heterogeneous group of disorders characterized by HYPERGLYCEMIA and GLUCOSE INTOLERANCE.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To explore the clinical characteristics of hyperglycemia in patients treated with olanzapine." | 8.81 | Olanzapine-associated diabetes mellitus. ( Doraiswamy, PM; Koller, EA, 2002) |
| " We assessed the differences in risk of developing diabetes mellitus during treatment with olanzapine and risperidone by using patients treated with haloperidol and fluphenazine as control subjects in whom we would not expect to see an increased risk." | 7.72 | Comparative study of the development of diabetes mellitus in patients taking risperidone and olanzapine. ( Fuller, MA; Grogg, AL; Secic, M; Shermock, KM, 2003) |
| "To report two cases of new-onset diabetes mellitus resulting after the initiation of olanzapine treatment." | 7.71 | Olanzapine-induced diabetes mellitus. ( Bonanno, DG; Botts, SR; Davydov, L, 2001) |
| " We report a 48 years old male drinker and addicted to cocaine, that after two months of Olanzapine use, developed a severe diabetes mellitus with fasting blood glucose values reaching 514 mg/dl." | 7.71 | [Diabetes mellitus induced by olanzapine. A case report]. ( Arancibia, P; Bravo, V; Rojas, P; Varela, S, 2001) |
| "To explore the clinical characteristics of hyperglycemia in patients treated with olanzapine." | 4.81 | Olanzapine-associated diabetes mellitus. ( Doraiswamy, PM; Koller, EA, 2002) |
| " We assessed the differences in risk of developing diabetes mellitus during treatment with olanzapine and risperidone by using patients treated with haloperidol and fluphenazine as control subjects in whom we would not expect to see an increased risk." | 3.72 | Comparative study of the development of diabetes mellitus in patients taking risperidone and olanzapine. ( Fuller, MA; Grogg, AL; Secic, M; Shermock, KM, 2003) |
| "To examine quantitatively the association between glucose intolerance including diabetes mellitus and the use of the atypical antipsychotics clozapine, olanzapine or risperidone, and to identify possible risk factors for the development of glucose intolerance during treatment with these drugs." | 3.71 | Glucose intolerance with atypical antipsychotics. ( Hägg, S; Hedenmalm, K; Mortimer, O; Spigset, O; Ståhl, M, 2002) |
| "To report two cases of new-onset diabetes mellitus resulting after the initiation of olanzapine treatment." | 3.71 | Olanzapine-induced diabetes mellitus. ( Bonanno, DG; Botts, SR; Davydov, L, 2001) |
| " We report a 48 years old male drinker and addicted to cocaine, that after two months of Olanzapine use, developed a severe diabetes mellitus with fasting blood glucose values reaching 514 mg/dl." | 3.71 | [Diabetes mellitus induced by olanzapine. A case report]. ( Arancibia, P; Bravo, V; Rojas, P; Varela, S, 2001) |
| "Olanzapine and clozapine have been associated with the greatest weight gain of the newer antipsychotics." | 1.31 | Clinical issues associated with maintenance treatment of patients with schizophrenia. ( Guthrie, SK, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (10.00) | 18.2507 |
| 2000's | 18 (90.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Koller, EA | 1 |
| Doraiswamy, PM | 1 |
| Koro, CE | 1 |
| Fedder, DO | 1 |
| L'Italien, GJ | 1 |
| Weiss, SS | 1 |
| Magder, LS | 1 |
| Kreyenbuhl, J | 1 |
| Revicki, DA | 1 |
| Buchanan, RW | 1 |
| Guthrie, SK | 1 |
| Wilson, DR | 1 |
| D'Souza, L | 1 |
| Sarkar, N | 1 |
| Newton, M | 1 |
| Hammond, C | 1 |
| Hedenmalm, K | 1 |
| Hägg, S | 1 |
| Ståhl, M | 1 |
| Mortimer, O | 1 |
| Spigset, O | 1 |
| Caro, JJ | 1 |
| Ward, A | 1 |
| Levinton, C | 1 |
| Robinson, K | 1 |
| Citrome, LL | 1 |
| Gupta, S | 1 |
| Dewan, V | 1 |
| Fuller, MA | 1 |
| Shermock, KM | 1 |
| Secic, M | 1 |
| Grogg, AL | 1 |
| Lee, DW | 1 |
| Fowler, RB | 1 |
| Tavakoli, SA | 1 |
| Arguisola, MS | 1 |
| Ober, SK | 1 |
| Hudak, R | 1 |
| Rusterholtz, A | 1 |
| Lindenmayer, JP | 2 |
| Patel, R | 1 |
| Rigalleau, V | 1 |
| Gatta, B | 1 |
| Bonnaud, S | 1 |
| Masson, M | 1 |
| Bourgeois, ML | 1 |
| Vergnot, V | 1 |
| Gin, H | 1 |
| Bonanno, DG | 1 |
| Davydov, L | 1 |
| Botts, SR | 1 |
| Nathan, AM | 1 |
| Smith, RC | 1 |
| Rojas, P | 1 |
| Arancibia, P | 1 |
| Bravo, V | 1 |
| Varela, S | 1 |
| Ramankutty, G | 1 |
| Meyer, JM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| An Open Label Trial of Ziprasidone as an Adjuvant for Clozapine- or Olanzapine-Associated Diabetes Mellitus or Impaired Fasting Glucose in Chronic Schizophrenia[NCT00351000] | Phase 4 | 24 participants (Actual) | Interventional | 2005-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Subjects on clozapine with adjunctive ziprasidone were compared to subjects on olanzapine with adjunctive ziprasidone on change in fasting glucose levels from baseline to study endpoint (week 6 - baseline) (NCT00351000)
Timeframe: baseline, week 6
| Intervention | mg/dL (Mean) |
|---|---|
| Clozapine Treatment With Adjunctive Ziprasidone | 5 |
| Olanzapine Treatment With Adjunctive Ziprasidone | -4.5 |
Subjects on clozapine with adjunctive ziprasidone were compared to subjects on olanzapine with adjunctive ziprasidone on change in fasting insulin levels from baseline to study endpoint (week 6 - baseline) (NCT00351000)
Timeframe: baseline, week 6
| Intervention | microIU/L (Mean) |
|---|---|
| Clozapine Treatment With Adjunctive Ziprasidone | 1 |
| Olanzapine Treatment With Adjunctive Ziprasidone | -0.9 |
3 reviews available for pirenzepine and Diabetes Mellitus
| Article | Year |
|---|---|
Olanzapine-associated diabetes mellitus.
Topics: Benzodiazepines; Diabetes Mellitus; Humans; Hyperglycemia; Olanzapine; Pirenzepine; Retrospective St | 2002 |
Safety in treating bipolar disorder.
Topics: Antimanic Agents; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Clozapine; Diabetes Melli | 2003 |
Hyperglycemia associated with the use of atypical antipsychotics.
Topics: Adolescent; Adult; Age Factors; Aged; Antipsychotic Agents; Benzodiazepines; Clozapine; Comorbidity; | 2001 |
17 other studies available for pirenzepine and Diabetes Mellitus
| Article | Year |
|---|---|
Assessment of independent effect of olanzapine and risperidone on risk of diabetes among patients with schizophrenia: population based nested case-control study.
Topics: Adult; Aged; Antipsychotic Agents; Benzodiazepines; Case-Control Studies; Cohort Studies; Diabetes M | 2002 |
Clinical issues associated with maintenance treatment of patients with schizophrenia.
Topics: Antipsychotic Agents; Benzodiazepines; Clinical Trials as Topic; Clozapine; Continuity of Patient Ca | 2002 |
New-onset diabetes and ketoacidosis with atypical antipsychotics.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Clozapine; Diabetes Mellitus; Diabetic Ketoacidosis; D | 2003 |
Glucose intolerance with atypical antipsychotics.
Topics: Adverse Drug Reaction Reporting Systems; Antipsychotic Agents; Bayes Theorem; Benzodiazepines; Chlor | 2002 |
The risk of diabetes during olanzapine use compared with risperidone use: a retrospective database analysis.
Topics: Aged; Antipsychotic Agents; Benzodiazepines; Cohort Studies; Diabetes Mellitus; Female; Follow-Up St | 2002 |
Efficacy should drive atypical antipsychotic treatment.
Topics: Age Factors; Antipsychotic Agents; Benzodiazepines; Diabetes Mellitus; Humans; Olanzapine; Pirenzepi | 2003 |
Potential risk of diabetes mellitus with the use of atypical antipsychotic medication.
Topics: Antipsychotic Agents; Benzodiazepines; Diabetes Mellitus; Humans; Male; Middle Aged; Olanzapine; Pir | 2003 |
Comparative study of the development of diabetes mellitus in patients taking risperidone and olanzapine.
Topics: Antipsychotic Agents; Benzodiazepines; Black People; Diabetes Mellitus; Humans; Male; Mood Disorders | 2003 |
Olanzapine/risperidone and diabetes risk.
Topics: Antipsychotic Agents; Benzodiazepines; Diabetes Mellitus; Humans; Olanzapine; Pirenzepine | 2003 |
Diabetic ketoacidosis in a patient treated with olanzapine, valproic acid, and venlafaxine.
Topics: Adult; Anticonvulsants; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Benzodiazepi | 2003 |
Hyperglycemia and olanzapine.
Topics: Antipsychotic Agents; Benzodiazepines; Blood Glucose; Comorbidity; Depressive Disorder; Diabetes Mel | 1999 |
Olanzapine-induced ketoacidosis with diabetes mellitus.
Topics: Antipsychotic Agents; Antisocial Personality Disorder; Benzodiazepines; Diabetes Mellitus; Diabetic | 1999 |
Diabetes as a result of atypical anti-psychotic drugs--a report of three cases.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Clozapine; Depressive Disorder; Diabetes Mellitus; Gly | 2000 |
Olanzapine-induced diabetes mellitus.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Blood Glucose; Diabetes Mellitus; Humans; Male; Olanza | 2001 |
[Diabetes mellitus induced by olanzapine. A case report].
Topics: Antipsychotic Agents; Benzodiazepines; Diabetes Mellitus; Humans; Male; Middle Aged; Olanzapine; Pir | 2001 |
Olanzapine-induced destabilization of diabetes in the absence of weight gain.
Topics: Antipsychotic Agents; Benzodiazepines; Blood Glucose; Body Weight; Diabetes Complications; Diabetes | 2002 |
A retrospective comparison of weight, lipid, and glucose changes between risperidone- and olanzapine-treated inpatients: metabolic outcomes after 1 year.
Topics: Adult; Aged; Anticonvulsants; Antipsychotic Agents; Benzodiazepines; Blood Glucose; Body Weight; Dia | 2002 |